Schizophrenia Research
Volume 118, Issue 1 , Pages 189-200 , May 2010

Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation

  • Florian Schlagenhauf

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • Corresponding Author InformationCorresponding author. Charité-Universitaetsmedizin Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany. Tel.: +49 30 450517257; fax: +49 30 450517910.
    • ,
  • Martin Dinges

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Anne Beck

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Torsten Wüstenberg

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Eva Friedel

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Theresa Dembler

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Rahul Sarkar

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Jana Wrase

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Jürgen Gallinat

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Georg Juckel

      Affiliations

    • Department of Psychiatry, Ruhr-University Bochum, Germany
    • ,
  • Andreas Heinz

      Affiliations

    • Department of Psychiatry, Charité-Universitaetsmedizin Berlin, Campus Mitte, Germany

Received 18 August 2009 ,Revised 4 January 2010 ,Accepted 28 January 2010.

References 

  1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002;22:3708–3719
  2. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry. 1999;156:1358–1366
  3. Barch DM, Smith E. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol. Psychiatry. 2008;64:11–17
  4. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res. Brain Res. Rev. 2000;31:251–269
  5. Bertolino A, Caforio G, Blasi G, De CM, Latorre V, Petruzzella V, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry. 2004;161:1798–1805
  6. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn. Sci. 2000;4:215–222
  7. Callicott JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb. Cortex. 1999;9:20–26
  8. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex. 2000;10:1078–1092
  9. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia — therapeutic implications. Biol. Psychiatry. 1999;46:1388–1395
  10. Carter CS, van Veen V. Anterior cingulate cortex and conflict detection: an update of theory and data. Cogn. Affect. Behav. Neurosci. 2007;7:367–379
  11. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287:2020–2022
  12. Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl.). 2004;174:111–125
  13. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 1991;11:1907–1917
  14. Dixon AL, Prior M, Morris PM, Shah YB, Joseph MH, Young AM. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology. 2005;48:236–245
  15. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 1995;378:180–182
  16. Durstewitz D, Seamans JK. The computational role of dopamine D1 receptors in working memory. Neural Netw. 2002;15:561–572
  17. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Personality Disorders, (SCID-II). Washington, D.C: American Psychiatric Press, Inc.; 1997;
  18. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York: New York State Psychiatric Institute; 2001;
  19. Fleischhacker WW. Aripiprazole. Expert Opin. Pharmacother. 2005;62:2091–2101
  20. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychol. Med. 2008;1–17
  21. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 1995;2:189–210
  22. Fumagalli F, Frasca A, Racagni G, Riva MA. Dynamic regulation of glutamatergic post-synaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol. Pharmacol. 2008;73(5):1484–1490
  23. Gibbs SE, D'Esposito M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl.). 2005;180:644–653
  24. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain Mapp. 2005;25:60–69
  25. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  26. Heinz A, Romero B, Gallinat J, Juckel G, Weinberger DR. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry. 2003;36(Suppl 3):S152–S157
  27. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431–436
  28. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1999;96:13432–13437
  29. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001;76:1521–1531
  30. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004;483:45–53
  31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  32. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry. 2007;64:633–647
  33. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl.). 2006;187:312–320
  34. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry. 2009;65:1024–1031
  35. Kotrla KJ, Weinberger DR. Brain imaging in schizophrenia. Annu. Rev. Med. 1995;46:113–122
  36. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatr. 1999;7:125–143
  37. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Tamminga CA. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry. 2003;53:601–608
  38. Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, et al. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology. 2004;29:171–178
  39. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated Talairach atlas labels for functional brain mapping. Hum. Brain Mapp. 2000;10:120–131
  40. Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. 2005;114:599–611
  41. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004;493:75–83
  42. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251–267
  43. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage. 2003;19:1233–1239
  44. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol. Psychiatry. 2000;48:99–109
  45. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, et al. Dextroamphetamine enhances “neural network-specific” physiological signals: a positron-emission tomography rCBF study. J. Neurosci. 1996;16:4816–4822
  46. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 2003;100:6186–6191
  47. Mehta MA, Montgomery AJ, Kitamura Y, Grasby PM. Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology (Berl.). 2008;196:157–165
  48. Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, et al. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256:522–531
  49. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002;5:267–271
  50. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch. Gen. Psychiatry. 2009;66:811–822
  51. Molina V, Gispert JD, Reig S, Sanz J, Pascau J, Santos A, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl.). 2005;178:17–26
  52. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004;72:29–39
  53. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9:97–113
  54. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum. Brain Mapp. 2005;25:46–59
  55. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry. 2006;11:118–119
  56. Ranganath C, Minzenberg MJ, Ragland JD. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol. Psychiatry. 2008;64:18–25
  57. Rowley HL, Needham PL, Kilpatrick IC, Heal DJ. A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 2000;361:187–192
  58. Schlagenhauf F, Wustenberg T, Schmack K, Dinges M, Wrase J, Koslowski M, et al. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur. Neuropsychopharmacol. 2008;18:589–599
  59. Schlosser RG, Koch K, Wagner G, Nenadic I, Roebel M, Schachtzabel C, et al. Inefficient executive cognitive control in schizophrenia is preceded by altered functional activation during information encoding: an fMRI study. Neuropsychologia. 2008;46:336–347
  60. Schmidt K, Metzler P. Wortschatztest (WST). Weinheim: Beltz test; 1992;
  61. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, et al. Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int. J. Neuropsychopharmacol. 1999;2:73–82
  62. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry. 2002;59:25–30
  63. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol. Psychiatry. 2006;59:919–928
  64. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 2007;10:376–384
  65. Weickert TW, Goldberg TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr. Psychiatry Rep. 2005;7:304–310
  66. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl.). 2002;162:11–17
  67. Wickens TD. Elementary signal detection theory. Oxford; New York: Oxford University Press; 2002;
  68. Williams GV, Castner SA. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience. 2006;139:263–276
  69. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376:572–575
  70. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex. 1998;8:321–345
  71. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64:663–667
  72. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005;8:457–472
  73. Woodward TS, Cairo TA, Ruff CC, Takane Y, Hunter MA, Ngan ET. Functional connectivity reveals load dependent neural systems underlying encoding and maintenance in verbal working memory. Neuroscience. 2006;139:317–325
  74. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 2005;387:157–161

PII: S0920-9964(10)00074-5

doi: 10.1016/j.schres.2010.01.022

Schizophrenia Research
Volume 118, Issue 1 , Pages 189-200 , May 2010

Article Tools

* Image Usage & Resolution